|Day Low/High||62.10 / 64.16|
|52 Wk Low/High||26.41 / 64.16|
Investors may want to look at some small-cap pharma names that could be takeover targets like Relypsa.
Following Galenica's $1.5 billion bid for Relypsa, investors are beginning to search for the next target.
At least one company follower believes the divestiture of Shire's Neurology division for as much as $13 billion would be a logical next move.
All of these add up to a level of insecurity on the part of sidelined money.
It's a pretty broad spectrum, but they've definitely arrived.
A call with investors Wednesday highlights drugs in the pipeline that could be attractive to bidders that reportedly include Sanofi, Pfizer and Celgene, among others.
A dovish Federal Reserve in June pushes equities, crude to close around session highs.
Stocks add to gains by late afternoon Wednesday after the Federal Reserve's June meeting minutes confirm members' prudent approach to monetary policy.
Crude oil returns to the red by late Wednesday morning, reversing a brief recovery, as stocks turn mixed.
An agreement by Medivation (MDVN) to share confidential information with French company Sanofi (SNY) has led to speculation of a potential merger.
Stock futures set up Wall Street for another slide on Wednesday as Brexit fears pull crude oil lower.
The company's shares were up nearly 2% in after hours trading.
There are renewed worries about Brexit as the British pound has fallen to a new 30 year low.
Medivation, Inc. (Nasdaq:MDVN) today issued a reminder that it will host an investor conference call and live audio webcast on Wednesday, July 6, 2016 at 4:30 p.
U.S. stock futures are lower Wednesday as European shares tumble and the British pound hits a new 31-year low.
The biopharmaceutical company has entered into confidentiality agreements with Sanofi and others.
Medivation, Inc. (NASDAQ:MDVN) today announced that it has entered into confidentiality agreements with a number of parties that have expressed interest in exploring a potential transaction and demonstrated that interest to...
Trade-Ideas LLC identified Medivation (MDVN) as a "barbarian at the gate" (strong stocks crossing above resistance with today's range greater than 200%) candidate
Cramer says Wynn is fantastic but he's avoiding Valeant.
When short-sellers get caught leaning the wrong way, that's a recipe for explosive moves to the upside, Cramer says.
Sanofi's $52.50 per share takeout offer for Medivation is looking increasingly unappealing.
Besides Sanofi, Biogen is the next most likely to complete a sizable transaction in the next 12 months, according to Credit Suisse analysts.
The Medivation bidder will swap its Merial animal care unit for Boehringer's over-the-counter operations and cash.
Medivation, Inc. (NASDAQ:MDVN) today announced that independent proxy advisory firm Glass, Lewis & Co.
Medivation, Inc. (NASDAQ:MDVN) today sent a letter to stockholders providing detailed information to correct the misleading claims Sanofi has made as part of its coercive efforts to acquire Medivation at an opportunistic,...
The French drugmaker is reportedly thinking about including a CVR in its $9.3 billion bid for Medivation, but the move is unlikely to be enough to entice the target's shareholders.